WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
